News
-
The MAP-AD® Test obtains the CE-IVDR mark, the first prognostic test for Alzheimer’s disease dementia
Barcelona – September 19, 2025 – ADmit Therapeutics S.L. announced today that its disruptive blood test for the prognosis of Alzheimer’s dementia, the MAP-AD® Test, has received the CE Mark under the In Vitro Diagnostic Regulation (IVDR, 2017/746). This certification confirms that the test complies with the European Union’s strict safety and performance standards, a significant milestone for…
-
ADmit Therapeutics publishes a key study on a new blood-based biomarker that predicts the progression to Alzheimer’s dementia
Barcelona – September 19, 2025– ADmit Therapeutics S.L. today announced the publication of a blood biomarker in the journal iScience (Cell Press). The study details the fundamental research that led to the development of the Test MAP-AD®, a prognostic solution based on mitochondrial DNA methylation levels in blood that predicts progression to Alzheimer’s dementia in patients with Mild Cognitive Impairment (MCI).…
-
ADmit Therapeutics is Attending the AAIC 2025 in Toronto
July 27, 2025. We are excited to announce that our company is attending the Alzheimer’s Association International Conference 2025 (AAIC25) in Toronto, Canada, from July 27 to July 31, 2025. The AAIC is the world’s largest and most influential meeting dedicated to advancing dementia science. Organized by the Alzheimer’s Association, this global forum brings together researchers, clinicians, and industry leaders to…
-
ADmit Therapeutics SL, one of the 10 most disruptive companies in Catalonia, according to ACCIÓ
Barcelona, July 16, 2025 — The company has been recognized as one of the startups and companies awarded the ‘Catalonia Exponential Leaders’ distinction by ACCIÓ, which acknowledges pioneers in the field of disruptive innovation for their ability to generate a positive impact on society beyond their business models, as well as their potential for exponential growth and adoption…
-
ADmit Therapeutics Relocates to New State-of-the-Art Facilities Within the Almirall’s Innovation Hub “The Hive”
Barcelona, Spain – July 2, 2025 – ADmit Therapeutics, a biotechnology company focused on developing innovative diagnostic solutions for Alzheimer’s disease, today announced its relocation to new, expanded laboratory and office spaces within Almirall’s Innovation Hub “The Hive” at the existing R&D center in Sant Feliu de Llobregat. This strategic move signifies a key milestone for…
-
ADmit Therapeutics receives accreditation from the College of American Pathologists
Barcelona, Spain – November 14, 2024. The Committee on Accreditation of the College of American Pathologists (CAP) has granted accreditation to ADmit Therapeutics, Barcelona, based on the results of the recent on-site inspection conducted as part of CAP’s Accreditation Programmes. The director of the laboratory, Dr. Marta Blanch was notified of this national recognition and…
